Keywords: رالتانگاریویر; Atazanavir; Raltegravir; HIV; NRTI-sparing antiretroviral therapy; Treatment-experienced patients;
مقالات ISI رالتانگاریویر (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: رالتانگاریویر; Raltegravir; LC–ESI–MS/MS; Negative ionization mode; Human plasma; Bioequivalence study
Keywords: رالتانگاریویر; Midazolam; Raltegravir; Ketoconazole; Ritonavir; Rifampin;
Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series
Keywords: رالتانگاریویر; Therapeutic drug monitoring; Darunavir; Etravirine; Raltegravir; Instantaneous inhibitory potential; Genotypic inhibitory quotient;
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA
Keywords: رالتانگاریویر; HIV-1 DNA; HIV-1 reservoir; Ultrasensitive HIV-1 RNA; Raltegravir; Integrase inhibitors;
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance
Keywords: رالتانگاریویر; ART; antiretroviral therapy; TasP; Treatment-as-Prevention; NRTI; nucleoside reverse transcriptase (RT) inhibitor; NNRTI; non-nucleoside RT inhibitor; PI; protease inhibitor; INSTI; integrase strand transfer inhibitor; RAL; raltegravir; EVG; elvitegravir;
Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy
Keywords: رالتانگاریویر; Integrase inhibitor; Raltegravir; Treatment intensification; 2-LTR; Multi-stage models;
Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals
Keywords: رالتانگاریویر; Raltegravir; Hepatitis; HCV; Tolerability; Safety; Efficacy
Dolutegravir for the treatment of HIV-2 infection
Keywords: رالتانگاریویر; HIV-2; Dolutegravir; Raltegravir; Antiretroviral therapy; Drug resistance;
Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients
Keywords: رالتانگاریویر; HIV-1; Polymorphisms; Raltegravir; UGT1A1
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance
Keywords: رالتانگاریویر; Raltegravir; Muscle symptoms; Creatine phosphokinase elevations;
Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir
Keywords: رالتانگاریویر; HTLV-2 proviral load; HIV-1 coinfection; Raltegravir;
A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C
Keywords: رالتانگاریویر; HIV; Hepatitis; Hepatitis C; Raltegravir; cART; Hepatotoxicity; Liver; Enzyme elevations; Co-infection
In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir
Keywords: رالتانگاریویر; Subtype A HIV-1; CRF01_AE HIV-1; Integrase; Raltegravir; Inhibition
HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil
Keywords: رالتانگاریویر; HIV-1; Brazil; Integrase; Raltegravir; Genotype; Resistance
Thermodynamics of complexes formation by ITC in methanol/water = 9/1 (v/v) solution: A case study
Keywords: رالتانگاریویر; HIV integrase inhibitor; Mg(II), Mn(II), Co(II) and Zn(II) complexes; Antiretroviral drug; Raltegravir; Isotermal titration calorimetry in mixed solvent; Complexes formation heats
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study
Keywords: رالتانگاریویر; HIV; Raltegravir; Salvage; Experienced; Resistance
Efficacy and safety of antiretrovirals in HIV-infected patients with cancer
Keywords: رالتانگاریویر; AIDS; antiretroviral; cancer; HIV; raltegravir;
Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase
Keywords: رالتانگاریویر; CPE; cytopathic effect; LEDGF/p75; lens epithelium-derived growth factor; DMAD; dimethylacetylenedicarboxylate; IN; integrase; PK; pharmacokinetics; PD; pharmacodynamics; RAL; raltegravir; ELV; elvitegravir; HIV-1 integrase inhibitors; INSTIs; 5-Hydroxy-6
Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: Design and characterization of the enzymatic properties
Keywords: رالتانگاریویر; HIV-1 integrase; Subtype A; Consensus; Catalytic activity; Raltegravir; Drug resistance;
Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance
Keywords: رالتانگاریویر; HIV-1 integrase; Drug resistance; Raltegravir; Molecular dynamics; NAMD;
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA databaseâ
Keywords: رالتانگاریویر; Drug resistance; genotype; human immunodeficiency virus type 1-1; raltegravir; virological response;
Increase in Transaminase Levels Following the Use of Raltegravir in a Woman With a High HIV Viral Load at 35 Weeks of Pregnancy
Keywords: رالتانگاریویر; Raltegravir; pregnancy; transaminase;
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
Keywords: رالتانگاریویر; Integrase; Inhibitor; Raltegravir; Mutations; Efficacy; HIV-1; Response
Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography–tandem mass spectrometry
Keywords: رالتانگاریویر; LC–MS/MS; Antifungals; Antibiotics; Raltegravir; Imatinib
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors
Keywords: رالتانگاریویر; HIV-1 integrase; Inhibit; Raltegravir; Sulfonamide;
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients
Keywords: رالتانگاریویر; Darunavir; Raltegravir; Ritonavir; Pharmacokinetics; Drug-to-drug interactions; HIV;
Development and evaluation of a thermosensitive vaginal gel containing raltegravir + efavirenz loaded nanoparticles for HIV prophylaxis
Keywords: رالتانگاریویر; Raltegravir; Efavirenz; Pre-exposure prophylaxis; Nanoparticles; HIV; Thermosensitive gel;
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy
Keywords: رالتانگاریویر; Raltegravir; Ritonavir-boosted protease inhibitor; LDL size; LDL phenotype; Lipoprotein-associated phospholipase A2;
A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts
Keywords: رالتانگاریویر; Raltegravir; Intracellular; HIV; LC-MS/MS; Integrase inhibitor;
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience
Keywords: رالتانگاریویر; Dolutegravir; S/GSK1349572; Raltegravir; Integrase; Drug resistance; HIV subtypes
Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir
Keywords: رالتانگاریویر; Integrase inhibitor; Feline leukemia virus; Antiretroviral therapy; Progressive infection; Raltegravir; Retrovirus
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors
Keywords: رالتانگاریویر; HIV-1 integrase; Inhibit; Raltegravir; Cycloaddition
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir
Keywords: رالتانگاریویر; Salvage therapy; Antiretrovirals; Drug resistance; Darunavir; Raltegravir; Etravirine; Human immunodeficiency virus type 1;
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption
Keywords: رالتانگاریویر; Genotype; HIV-1; integrase inhibitors; raltegravir; resistance mutations
Indicación de uso de los antirretrovirales de última generación en la práctica clÃnica actual
Keywords: رالتانگاریویر; Darunavir; Maraviroc; Etravirina; Raltegravir; Resistencia multiple a medicamentos; Tratamiento antirretroviral; Infección por VIH; Darunavir; Maraviroc; Etravirine; Raltegravir; Multiple drug resistance; Antiretroviral treatment; HIV infection;
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor
Keywords: رالتانگاریویر; HIV-1; Integrase; Raltegravir; Resistance; MK-2048
Structural biology of retroviral DNA integration
Keywords: رالتانگاریویر; HIV-1; Prototype foamy virus; Integrase; Integration; AIDS; Integrase strand transfer inhibitor; Raltegravir; Structural biology; X-ray crystallography;
Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection
Keywords: رالتانگاریویر; Raltegravir; High-performance liquid chromatography; Photodiode array detection
Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection
Keywords: رالتانگاریویر; Raltegravir; Integrase inhibitor; Female genital tract; Cervicovaginal fluid; Solid-phase extraction; High-performance liquid chromatography
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
Keywords: رالتانگاریویر; HIV; Darunavir; Triple-class drug resistance; Raltegravir; Enfuvirtide; Etravirine
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
Keywords: رالتانگاریویر; HIV-1; Antiretroviral resistance; Deep sequencing; Raltegravir; Evolution
LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor
Keywords: رالتانگاریویر; Process development; Raltegravir; LCMS; QTof; Impurity identification
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles
Keywords: رالتانگاریویر; HIV; integrase; raltegravir; resistance; MK-2048
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Keywords: رالتانگاریویر; HIV infections/virology; Enfuvirtide; Raltegravir; Patient satisfaction; Skin/drug effects
Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration
Keywords: رالتانگاریویر; HIV-1; AIDS; Integrase; Integration; Integrase strand transfer inhibitor (InSTI); High-throughput; Scintillation proximity assay; Raltegravir;
Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography–electrospray tandem mass spectrometry
Keywords: رالتانگاریویر; Raltegravir; Raltegravir glucuronide; Mass spectrometry; In-source transformation
Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses
Keywords: رالتانگاریویر; HIV; Integrase; Inhibitor; Resistance; Selection; InSTI; Replication capacity; Raltegravir;
Les nouvelles molécules anti-VIHÂ : la place du raltégravir
Keywords: رالتانگاریویر; Raltégravir; Inhibiteur d'intégrase; Antirétroviraux; Raltegravir; Inhibitors of integrase; Antiretroviral drugs;
Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry
Keywords: رالتانگاریویر; Raltegravir; LC–MS/MS; HIV; Pharmacology; Dried blood spots